Gossamer Bio Reports Q3 2026 Results, Submits Seralutinib NDA

Gossamer Bio reported third-quarter 2026 revenue of $38.4 million and a net loss of $48.1 million. Cash, cash equivalents and marketable securities totaled $51.2 million at September 30, 2026. The company submitted a New Drug Application for seralutinib in pulmonary arterial hypertension to the FDA…